Human Systems
Latest Innovations | ||
---|---|---|
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
Dr. Zhao from the University of Illinois at Urbana-Champaign has developed a novel method for combinatorial genome... |
Dr. Zhao from the University of Illinois at Urbana-Champaign has developed a novel method for combinatorial genome editing in yeast. With the use of CRISPR-AID technology targeted genes can be simultaneously upregulated, downregulated, and deleted allowing discovery of synergistic effects to enhance strain phenotypes. Utilizing this technology will allow fast generation of novel strains suited to industrial applications. In addition Dr. Zhao has generated novel CRISPR constructs optimized for CRISPRa and CRISPRi applications for use in yeast. This is the first use of orthogonal CRISPR strains in yeast and will greatly expand the toolbox for yeast genome engineering. |
MRSI Improvements
Dr. Liang from the University of Illinois at Urbana-Champaign has developed new MRI acquisition methods and post-acquisition data processing techniques that allow for a...
Dr. Liang from the University of Illinois at Urbana-Champaign has developed new MRI acquisition methods and post-acquisition data processing techniques that allow for a standard MRI instrument to perform traditional spin density imaging as well as susceptibility mapping, quantitative susceptibility mapping, and metabolite mapping with high resolution and signal to noise ratio from a single scan. Unlike other techniques, such as CT scans, the current technology does not require ionizing radiation and is thus safer for patients and radiology professionals.
Small Molecules With Antibacterial and Anticancer Activity
Dr. Hergenrother from the University of Illinois at Urbana-Champaign has developed a series of topoisomerase inhibiting small molecules...
Dr. Hergenrother from the University of Illinois at Urbana-Champaign has developed a series of topoisomerase inhibiting small molecules with anticancer activity. These molecules possess comparable activity and selectivity to doxorubicin, a common cancer chemotherapy drug, across a range of cancer cell lines. These small molecules are a promising alternative to cardiotoxicity producing doxorubicin as a cancer chemotherapy drug. These molecules are also useful as broad-spectrum antibiotics capable of treating resistant bacteria strains (minimum inhibitory concentrations as low as 0.5 micrograms/mL for S. aureus and E. coli).